Cannabinoid Hyperemesis Syndrome: Rare or Underdiagnosed?

Main Article Content

Selena Au
Ali Rezaie

Keywords

Abstract

A 38-year-old male presented to the emergency department with severe acute-on-chronic abdominal pain. For the previous 20 years, he had experienced daily sharp epigastric pain with generalization to the entire abdomen. The pain typically began late in the morning and could last from hours to days. It was associated with nausea, vomiting, diaphoresis, and occasionally fever, diarrhea, and fatty or bloody bowel movements. These symptoms were not associated with food consumption. Over the previous five years, the patient had lost over 20 kg in weight and had noticed a marked decline in his performance at work and in the quality of his leisure time. He found symptom relief by smoking rolled marijuana cigarettes (“joints”), which he had been using three times per day since his teens. His pain crises were alleviated only with soaking in a tub of “scalding hot” bath water which he drew up ritualistically every morning. The patient’s symptoms had previously been investigated by his family physician, who suspected acute intermittent porphyria (AIP), but it is unclear what medical diagnostics had been performed. Quetiapine (50 mg qhs) had been prescribed and started one year prior to presentation, but during a review of systems, the patient denied having had any psychiatric symptoms. His medical history was significant only for smoking and lactose intolerance. Review of systems and family history were negative for autoimmune, infectious, malignant, or inflammatory bowel disease. When questioned as to why he chose to come to the emergency department just then, the patient replied that his family physician had suggested that he present during one of the more severe pain crises in order to allow laboratory work-up to confirm the diagnosis of AIP. At the time of presentation, the patient had been ill for the previous four days. On examination, the patient was febrile (38.6oC), hypertensive (195/113), and markedly dehydrated. He was of thin habitus and had normal results on cardiorespiratory examination. His abdomen was nondistended but diffusely tender. Abdominal rigidity with guarding was noted by the emergency physician but was absent on reassessment by internal medicine. The patient’s laboratory investigation results were consistent with a stress response and dehydration, including hemoglobin = 193 g/L, white blood cell count = 20 × 109 g/L, creatinine = 164 μmol/L, and lactate = 2.7 mmol/L. Liver enzymes and the results of tests of hepatic synthesis were normal. Urine porphobilinogen at the time of crisis was negative for AIP. Upon a review of the literature, a diagnosis of cannabinoid hyperemesis syndrome was made. To rule out other organic etiologies, the patient underwent abdominal computed tomography, which was unremarkable. Upper gastrointestinal endoscopy with gastric biopsies revealed no pathology.
Abstract 372 | PDF Downloads 521 HTML Downloads 876

References

1. Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004;53:1566–70.

2. Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 2012;87:114–9.

3. Sofka S, Lerfald N. Cannabinoid hyperemesis syndrome: a case series. W V Med J 2013;109:20–3.

4. Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc 2009;84:76–8.

5. Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 2013;45:544–6.

6. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med 2013;31:1003.e5–6.

7. Roelofs J, Vorel SK, Vorel-Havelkova E, Brombacher PJ. [Cannabinoid hyperemesis with the unusual symptom of compulsive bathing.] Ned Tijdschr Geneeskd 2005;149:2376.

8. Cox B, Chhabra A, Adler M, et al. Cannabinoid hyperemesis syndrome: case report of a paradoxical reaction with heavy marijuana use. Case Rep Med 2012;2012:757696.

9. Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada. Statistics Canada catalogue no. 82-624-X. Ottawa: Statistics Canada, 2013 Sept [cited 2013 Nov]; http://www.statcan.gc.ca/pub/82-624-x/2013001/ article/11855-eng.pdf.

10. Wingrove J. Patients, doctors upset by Canada’s commercialization of marijuana. The Globe and Mail 2013 Oct 3 [cited 2013 Nov 13]; http://www. theglobeandmail.com/news/national/patients-doctors-upset-by-canadascommercialization- of-marijuana/article14693911/.

11. Health Canada. Ottawa: Health Canada, 2013 Jun 10 [cited 2013 Nov 13]; http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2013/2013-79-eng.php.

12. Sullivan S. Cannabinoid hyperemesis. Can J Gastroenterol 2010;24:284–5.